Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases
Authors' conclusion
The OMERACT GC Impact Working Group has developed and agreed upon detailed domain definitions for core domains.
Study context
- Population
- Stakeholder groups (patient research partners, health care professionals, clinician researchers, industry members and methodologists); OMERACT Glucocorticoid (GC) Impact Working Group, 2021–2023
- Outcome
- Definitions of the mandatory domains of the OMERACT GC impact core domain set
Methodological detailsOMERACT methodology, evidence and consensus-based decision making of all stakeholder groups, synthesis of qualitative studies, quantitative work and Delphi rounds, Virtual meetings between 2021 and 2023
- OMERACT methodology
- Evidence and consensus-based decision making of all stakeholder groups
- Synthesis of qualitative studies, quantitative work and Delphi rounds
- Virtual meetings between 2021 and 2023
Recommendations
As reported in the abstract
- All domains primarily in the Pathophysiological Manifestations Core Area, except Fatigue (primarily Life Impact) and Weight (spanning both Core Areas)
- Sources of variability: cultural factors, age, gender, education level, socioeconomic status, personal experiences, emotional state, language barriers
Original publication
Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases. Semin Arthritis Rheum. Published 16 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →